higher frequencies as well as absolute numbers of CD8 + CD3 -lymphocytes are linked to 48 delayed HIV-1 disease progression. We show that the majority of these cells are well-49 described blood NK cells. In a subsequent cross-sectional study we demonstrate a significant 50 
Materials and Methods

106
Study subjects. The data presented in this study is derived from a cohort of altogether 162 107 HIV-seropositive patients and 15 uninfected control subjects. From the 162 HIV-infected 108 patients, 117 untreated subjects with CD4 + T cell counts above 500 cells/μl were 109 longitudinally followed at our institution for up to 90 months with a median follow-up time of 110 30.6 months (interquartile range 18.5 to 50.4). A description of this longitudinal patient cohort 111 is provided in Table 1 . Peripheral blood samples from 60 untreated HIV-seropositive subjects 112 chosen based on sample availability were analyzed in a cross-sectional study. 25 of these 60 113 patients were part of the longitudinal study but none of these samples were taken at baseline 114 or endpoint. Blood samples for the cross-sectional study were taken at random time points 115 during patient's visits after study recruitment and thus encompass various clinical stages. To 116 study the effect of ART on CD8 expression on NK cells, samples from 28 patients at least one 117 year on ART with suppressed viral loads were analyzed (8/28 overlap with longitudinal 118 cohort). We obtained samples from 21 individuals before and after the initiation of ART (9/21 119 overlap with longitudinal cohort). All study subjects were recruited at the HIV outpatient 120 clinic of the Medizinische Hochschule Hannover (MHH) and gave written, informed consent 121 prior to their participation. The study was approved by the local ethics committee (Votum der 122
Ethikkommission der MHH No. 3150). Plasma HIV-1 RNA levels was measured using the 123 COBAS TaqMan HIV-1 test (Roche Diagnostics) with a lower limit of detection of 34 124 copies/mL. NK cell, CD4 + and CD8 + T cell as well as CD8 + CD3 -lymphocyte counts were 125 routinely determined by a flow cytometry-based assay using CYTO-STAT tetra CHROME 126 
CD3
-lymphocyte counts still exhibited prolonged survival (Fig. 1E ). Since 209
there were an unusually high number of elite controllers in our cohort (defined as 210 on November 13, 2017 by guest http://jvi.asm.org/ undetectable viral loads during at least three visits during a period of 12 months or longer) we 211 sought to address if these could potentially influence our survival analysis. After exclusion of 212 these 7 patients we still found the survival difference to be statistically significant (Fig. 1F) We also included 15 HIV-seronegative control subjects. After gating on CD8
lymphocytes, a subsequent analysis of CD56 and CD16 expression revealed that the majority 233 of these cells are previously well-defined peripheral blood NK cell subsets, namely, CD56 bright 234 (4.7% ± 2.2% SD and 6.3% ± 5.4% SD, HIV patients and control subjects, respectively), 235
+ (74% ± 11.6% SD and 50% ± 22.9% SD) and CD56 -CD16 + (6.7% ± 4.1% SD 236 on November 13, 2017 by guest http://jvi.asm.org/ and 19.3% ± 12.2% SD) cells ( Fig. 2A, B ). We and others previously reported a decrease of 237 NK cell counts (>230 cells/μl) were associated with a delayed onset of disease progression 257 compared to subjects with lower NK cell numbers (Fig. 2C , Suppl. Table 1A ). Elevated 258 relative NK cell frequencies (>10,3%) were associated with a modestly improved clinical 259 outcome (Fig. 2D) we performed 9-to 10-color polychromatic flow cytometry and were able to employ an 284 improved gating strategy. We excluded doublets and dead cells and defined NK cells as CD3 uninfected control subjects (Fig. 3A, B) . Importantly, the samples from untreated HIV 290 patients were randomly taken and thus represent a variety of clinical stages of HIV 291 immunopathogenesis. We observed substantially lower frequencies of CD8 + NK cells in 292 untreated HIV-1 infected individuals compared to healthy controls (Fig. 3B) , which was 293 partially restored after one year of ART. To further investigate the effect of antiviral 294 treatment, we performed a follow-up study in previously untreated patients one year after the 295 initiation of ART. Both, the relative numbers as well as the absolute counts of CD8 + NK cells 296 were significantly increased in patients after receiving antiviral treatment (Fig. 3C) . In 297 summary, we show that HIV-infection leads to a significant decline of CD8 + NK cells. Our 298 cross-sectional as well as longitudinal patient data indicate that antiretroviral treatment can 299 restore the number of CD8 + NK cells almost to levels comparable to uninfected control 300 subjects. 301
To further explore the relationship between HIV disease states and the frequency of CD8 percentages of CD8-expressing cells and the CD4/CD8 T cell ratio although the result did not 312 reach statistical significance (r = 0.1, P = 0.1; Fig. 3G (Fig. 4A ) nor in uninfected control subjects (Suppl. Fig. 1B ) 324
were we able to find significant differences in the percentages of cells expressing CD62L, 325 CD69, CD2, CD94, NKG2D, NKp30, NKp46, NKp80, CD85j, NKG2A and KIR2DL2/DL3. 326
We also measured PD-1 expression on NK cells. PD-1 expression was detectable on NK cells 327 ex vivo in several subjects but we found no difference in the frequency of cells expressing PD-328 1 when comparing CD8 + to CD8 -NK cells (data not shown). 329
The absence of notable phenotypic differences when studying NK cell receptors one at a 330 time prompted us to investigate the co-expression patterns of either inhibiting or activating 331 NK cell receptors. To this end, we performed Boolean gating analysis for the inhibiting 332 receptors CD85j, KIR2DL2/DL3 and NKG2A or activating receptors NKG2D, NKp30, 333
NKp46 and NKp80 on either CD8 + or CD8 -NK cells. Neither in HIV-infected patients (Fig.  334 4B, C) nor in uninfected control subjects (data not shown) were we able to find substantial 335 differences in the majority of the co-expression patterns of these receptors in CD8
+ compared 336 to CD8 -NK cells. Statistically significant differences in frequencies were found for NK cells 337 expressing only NKp30 among activating receptors and only NKG2A among inhibiting 338 receptors, which were both higher among CD8 -NK cells (Fig. 4B, C 
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-counterpart (Suppl. Fig. 1C) . We also observed a modest difference in HIV-1 345 seropositive individuals (Fig. 4D) HIV-seropositive subjects as well as uninfected controls (Fig. 5C, D) . In a similar vein, the 382 frequencies of cells performing none of the four functions were higher in the CD8 -NK cell 383 subpopulation compared to CD8 + cells (Fig. 5C ). Since these data were derived from 384 untreated HIV-1 seropositive patients with varied viral loads, we divided the patients into 385 groups with viral loads below or above 10,000 copies/ml. With the exception of one outlier, 386 polyfunctional cells were not increased in CD8 + NK cells compared to CD8 -in patients with 387 viral loads above 10,000 copies/ml. The majority of individuals with enhanced functional 388 activities of CD8 + NK cells were found in HIV-seropositive subjects with viral loads below 389 10,000 copies/ml (Fig. 5D) . 390 on November 13, 2017 by guest http://jvi.asm.org/ We also sought to determine the proliferative activity of CD8 + and CD8 -NK cells ex vivo. 391
To this end, we analyzed the intracellular expression of Ki-67, a marker associated with 392 cycling cells. As shown previously (18, 34), a greater number of Ki-67 + cells were observed 393 in untreated HIV-infected individuals compared to uninfected subjects (Suppl. Fig. 2C) . 394
However, we were unable to detect differences in the relative frequencies Ki-67 + cells in 395
+ compared to CD8 -NK cells, both in HIV-infected as well as uninfected subjects 396 (Suppl. Fig. 2C ). This finding suggests that the prevalence of cycling cells among CD8 + NK 397 cells is similar compared to CD8 -NK cells. α, MIP-1β and CD107a) were analyzed in 9 healthy control subjects and untreated HIV-809 infected patients with either high (>10,000 copy/mL, n=8) or low viral loads (<10,000 810 copy/mL, n=12). 811 812 
